EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions

Jessica Chu, Erika Panfen, Linna Wang, Anthony Marino, Xue-Qing Chen, R Marcus Fancher, Raviraj Landage, Omprakash Patil, Salil Dileep Desai, Devang Shah, Yongjun Xue, Michael Sinz und 1 weitere

Pharmaceutical Research · 2023

DOI: 10.1007/s11095-023-03563-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2023. Verfasst von Jessica Chu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb Research and Development, Princeton, NJ, 08543, USA. Hauptthemen laut MEDLINE: ATP-Binding Cassette Transporters, Neoplasm Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The differences between intestinal and systemic (hepatic and renal) P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) roles in drug disposition are difficult to define. Accordingly, we characterized Encequidar (ECD) as an intestinal P-gp and BCRP specific inhibitor to evaluate their role in drug disposition. METHODS: We assessed the in vitro and in vivo inhibition potential of ECD towards human and animal P-gp and BCRP. RESULTS: ECD is a potent inhibitor with a high degree of selectivity in inhibiting human P-gp (hP-gp) over human BCRP (hBCRP) (IC50s of 0.0058 ± 0.0006 vs. > 10 µM, respectively). In contrast, ECD is a potent inhibitor of rat and cynomolgus monkey BCRP (IC50 ranged from 0.059 to 0.18 µM). While the AUC of IV paclitaxel (PTX) was significantly increased by elacridar (ELD) (P < 0.05) but not ECD in rats (15 mg/kg; PO) (2.55- vs. 0.93-fold), that of PO PTX was significantly elevated to a similar extent between the inhibitors (39.5- vs. 33.5-fold). Similarly, the AUC of PO sulfasalazine (SFZ) was dramatically increased by ELD and ECD (16.6- vs. 3.04-fold) although that of IV SFZ was not significantly affected by ELD and ECD in rats (1.18- vs. 1.06-fold). Finally, a comparable ECD-induced increase of the AUC of PO talinolol in cynomolgus monkeys was observed compared with ELD (2.14- vs. 2.12-fold). CONCLUSIONS: ECD may allow an in-depth appraisal of the role of intestinal efflux transporter(s) in drug disposition in animals and humans through local intestinal drug interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP-Binding Cassette TransportersNeoplasm ProteinsHumansRatsAnimalsATP Binding Cassette Transporter, Subfamily G, Member 2Macaca fascicularisPaclitaxelDrug Interactions

Stichwörter der Autor:innen

P-glycoproteinbreast cancer resistance proteindrug-drug interactionintestinal absorption

Substanzen

ATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsPaclitaxel

Autor:innen und Institutionen

  • Departments of Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb Research and Development, Princeton, NJ, 08543, USA.
  • Nonclinical Disposition & Bioanalysis, Bristol Myers Squibb Research and Development, Princeton, NJ, 08543, USA.
  • Discovery Pharmaceutics, Bristol Myers Squibb Research and Development, Princeton, NJ, 08543, USA.
  • Pharmaceutical Candidate Optimization, Biocon Bristol Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Bommasandra IV Phase, Bangalore, 560099, India.
  • Departments of Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb Research and Development, Princeton, NJ, 08543, USA. hong.shen1@bms.com.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Chu, J., Panfen, E., Wang, L., Marino, A., Chen, X. Q., Fancher, R. M., Landage, R., Patil, O., Desai, S. D., Shah, D., Xue, Y., Sinz, M., & Shen, H. (2023). Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions. Pharmaceutical Research. https://doi.org/10.1007/s11095-023-03563-4

Vancouver

Chu J, Panfen E, Wang L, Marino A, Chen XQ, Fancher RM, et al. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions. Pharmaceutical Research. 2023. doi:10.1007/s11095-023-03563-4

BibTeX
@article{Chu2023,
  author = {Chu, Jessica and Panfen, Erika and Wang, Linna and Marino, Anthony and Chen, Xue-Qing and Fancher, R Marcus and Landage, Raviraj and Patil, Omprakash and Desai, Salil Dileep and Shah, Devang and Xue, Yongjun and Sinz, Michael and Shen, Hong},
  title = {Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions},
  journal = {Pharmaceutical Research},
  year = {2023},
  doi = {10.1007/s11095-023-03563-4}
}
Kostenlos starten →